Empowering patients, transforming lives

Cenofex Innovations is poised to make a significant impact in the treatment of lymphoedema. With its novel technology, Cenofex aims to provide an accessible, scalable, and convenient solution for the millions of patients who suffer from this debilitating condition. By delivering outstanding clinical results and a superior patient experience, Cenofex is set to revolutionize the $5+ billion lymphoedema device market and make a meaningful impact in the lives of patients.

With a strong focus on innovation, patient-centered design, and clinical outcomes, Cenofex is dedicated to improving the standard of care for those affected by lymphoedema and making a positive impact in the healthcare industry.

Our mission is to develop innovative biosensor technology that can help people monitor their health and well-being in real-time. We aim to create products that are affordable, easy-to-use, and accessible to everyone. We empower patients worldwide by returning freedom, functionality, and dignity to their lives.
Our vision is to revolutionise the healthcare industry with cutting-edge technology that truly makes a difference, delivering tangible value to patients across the globe. We are committed to conducting our business with unwavering social responsibility, and minimising our environmental footprint. By doing so, we strive to become the leader in our field, setting the standard for excellence in innovation, ethics, and impact.
At Cenofex Innovations, we are committed to fostering a diverse, inclusive, and equitable workplace. We believe that a diverse and representative workforce not only benefits our employees, but also drives innovation and helps us better serve our customers. We are dedicated to creating a workplace where all employees feel valued, respected, and have equal opportunities to grow and succeed. This includes, but is not limited to, diversity in race, ethnicity, gender, age, religion, sexual orientation, ability, and cultural background. We are continuously working towards building a more diverse and inclusive workplace and actively seek to attract and retain a diverse range of talent.
At Cenofex Innovations, we believe that patient-centred care is the foundation of all good medical care. That's why we design and develop our medical devices with the patient in mind. We want to make sure that our devices are easy to use, comfortable, and effective. We also want to make sure that our devices are affordable and accessible to everyone who needs them.
We are committed to innovation in the medical device industry. We believe that new technologies have the potential to improve the lives of patients and healthcare providers. That's why we are constantly investing in research and development. We are also committed to partnering with other innovative companies in the medical device industry.
We believe that collaboration is essential to success in the medical device industry. That's why we partner with a wide range of stakeholders, including patients, healthcare providers, regulators, and other companies. We believe that by working together, we can create better medical devices that improve the lives of patients.
We are committed to sustainability in all aspects of our business. That's why we design and develop our medical devices with sustainability in mind. We use recycled materials whenever possible, and we design our devices to be energy-efficient. We also believe in giving back to the community. That's why we donate a portion of our profits to organizations that support the health and well-being of patients.

The team

Sheridan is a founder and the CEO of Cenofex Innovations, a medical device startup based in NSW, Australia. With a BSc (Hons) in Exercise Science and a PhD in Biomechanics from the University of Wollongong, Sheridan brings over 12 years of experience in social and health research and biomechanics to the company. As the CEO, she is responsible for leading clinical research, managing stakeholder relationships, and developing business strategy. Sheridan's achievements include being a NSW Health-Rosenman Institute Scholar (2016-17) at UCSF, an Honorary Fellow at the Illawarra Health and Medical Research Institute (2020-Present), and an alumna of the SBE Australia Life Science Program (2020). In 2021, she was awarded the REDI Industry Placement in the BridgeTech Program. With her strong background and expertise, Sheridan is poised to lead Cenofex Innovations to success in the medical device industry.

Michael is a founder and the CTO of Cenofex Innovations. With a BEng (Hons) in Mechatronics and a PhD in Medical Radiation Physics from the University of Wollongong, Michael brings over 12 years of experience in physics and mechatronic engineering to the company. As the CTO, he is responsible for technology, verification testing, and product development. Michael's achievements include being a NSW Health-Rosenman Institute Scholar (2016-17) and an Honorary Associate Fellow at the University of Wollongong (2015-Present). With his extensive background in physics and engineering, Michael is a valuable asset to the team and is dedicated to driving the success of Cenofex Innovations through technology and innovation.

Chris is the Lead Engineer at Cenofex Innovations. With a BSc in Nanotechnology and a PhD in Biomechanics from the University of Wollongong, Chris brings over 10 years of experience in materials R&D across research institutions and industry to the company. As the Lead Engineer, Chris is responsible for the development of sensing technology and product development. His achievements include being awarded the HDR Industry Scholarship at the University of Wollongong (2017-2020) and the REDI Industry Placement in the BridgeTech Program (2022). With his extensive background in nanotechnology and biomechanics, Chris is a valuable asset to the team and is dedicated to driving the success of Cenofex Innovations through innovative engineering solutions.

Our capabilities

  • Systematic analytical research

    We base our concepts on systematic analytical research, drawing on the latest peer-reviewed evidence to inform our designs. We then use systematic research to evaluate the validity and reliability of our products.

  • Novel sensor development

    With our expertise across biomechanics, mechatronics, materials, and software engineering, we are able to produce novel bio-sensor devices from concept to fully functional prototype, in-house.

  • Rapid advanced prototyping

    Our full-spectrum of in-house rapid prototyping enables us to develop design concepts into advanced prototypes quickly and efficiently. This allows us to test our designs and make changes quickly.

  • Human-centric design

    We believe that understanding the user journey and experience is key to delivering the best care, while also identifying and capturing new value pools. That’s why we focus on delivering a seamless customer experience that meets user needs.

  • Data integration & analytics

    We understand the importance of data integration and analytics in capturing value from digital health solutions. By integrating data from multiple sources, we gain insights into user health and behaviour that help us develop more effective solutions.

  • Computer-aided engineering

    We use state-of-the art CAE software to simulate and test our designs before creating physical prototypes. This helps us reduce costs and speed up the development process.

Awards & Recognitions

The Rosenman Institute combines QB3’s resources for entrepreneurs with mentorship from the Rosenman Fellows, a group of medical device specialists with expertise in fields including engineering, IP law, and regulatory affairs.

Cenofex Founders Drs Gho and Weaver were the inaugural NSW Health Rosenman Institute Scholars, awarded a two-year fellowship at the institute, housed within UCSF (2015-17).

Rosenman Institute

Davies Collison Cave (DCC) specialises in IP litigation and in all commercial aspects of IP including commercial agreements, licensing, privacy and data protection, technology, media and telecommunications.

Cenofex Innovations was awarded a $10,000 prize to undertake IP work with DCC.

DCC

Brandwood Biomedical (now Pharmalex) was an Australian consultancy that provided international regulatory, reimbursement, and product development consultancy for medical devices and in vitro diagnostics.

Cenofex Innovations was awarded a $10,000 prize to develop a regulatory strategy with Brandwood.

Brandwood Biomedical

The NSW Medical Devices Fund is a competitive grant program run by NSW Health. It encourages investment in the commercialisation of medical devices in New South Wales. The Fund provides support to innovators to take local innovations to market and increase the uptake of New South Wales medical devices by the health system where they are cost effective and contribute to improving patient outcomes.

Cenofex Innovations was awarded $1.5M from the NSW MDF in 2018.

NSW Health

The MTP-Connect - REDI Placement Fellowship is an initiative of the Researcher Exchange and Development within Industry (REDI) program. It is made possible by the Medical Research Future Fund (MRFF) and operated by MTPConnect. The REDI Fellowship Program ensures workforce skills align with industry needs and drive industry-research-clinical-entrepreneurship connections. The program provides industry experiences and skills development for students, researchers, clinicians, MTP (medical technology, biotechnology and pharmaceutical) sector professionals.

Cenofex CEO Dr Gho and Lead Engineer Dr Richards were awarded REDI placement fellowships in 2021 and 2022 respectively.

MTP Connect

Current collaborations

Cenofex Innovations is deeply grateful to NSW Health for the invaluable support provided through the Medical Device Fund (MDF). This prestigious, game-changing fund empowers us to accelerate the development and commercialisation of our cutting-edge medical technologies, ultimately enhancing patient care and outcomes.

NSW Health's recognition and financial support through the MDF grant not only validate our innovative solutions but also strengthen our commitment to revolutionising healthcare. Together, we strive to make a lasting impact on patients' lives and the future of the medical industry.

Virtimachi specialises in the industrial design and development of novel medical devices and instruments and, like Cenofex, they are committed to improving the lives of patients through the development of high-quality, user-centered devices. Virtimachi are working with Cenofex to examine the usability of our lymphoedema management device through robust human-factor studies.

Cenofex Innovations collaborates with Pharmalex, a global leader in regulatory affairs and compliance. With our shared commitment to patient safety and healthcare innovation, our partnership ensures that Cenofex's ground-breaking medical solutions seamlessly navigate the complex regulatory landscape.

Pharmalex's expertise supports Cenofex in meeting stringent regulatory requirements, accelerating product development timelines, and ensuring the highest quality standards in our life-enhancing devices. Together, we are dedicated to transforming healthcare and delivering breakthrough technologies to patients worldwide.

The Aikenhead Centre for Medical Device Development (ACMD) is Australia’s first collaborative, hospital-based biomedical engineering research centre. ACMD's commitment to creating a thriving ecosystem for healthcare advancement aligns seamlessly with Cenofex's mission to transform patient care through groundbreaking technologies.

By partnering with ACMD, we gain access to a network of exceptional researchers, state-of-the-art facilities, and invaluable industry insights. Together, we work towards overcoming healthcare challenges and delivering life-enhancing solutions to patients across Australia and beyond.

Cenofex Innovations partners with the Illawarra Health and Medical Research Institute (IHMRI) in our pursuit of clinical excellence. IHMRI's dedication to advancing healthcare through world-class research and patient-centered solutions aligns perfectly with our mission to transform lives with cutting-edge medical innovations.

Our partnership with IHMRI enables us to access a network of top-tier clinical researchers and state-of-the-art facilities, ensuring our medical devices undergo stringent testing and validation. Together, we are committed to improving patient outcomes and fostering the future of healthcare through rigorous clinical work.

Cenofex Innovations partners with Davies Collison Cave (DCC), a leading intellectual property and legal firm, to protect our innovative medical technologies. With DCC's expertise in managing complex IP matters, we confidently safeguard our valuable intellectual assets, ensuring our breakthrough inventions receive the best legal protection. Our collaboration with DCC not only fortifies our position in the global market but also fosters a secure foundation for continued innovation and growth.

Connections

Cenofex Innovations is grateful for the support and opportunities provided by the MTP-Connect Researcher Exchange and Development within Industry (REDI) program. This prestigious program is designed to accelerate the growth and success of high-potential participants in the medical technology and pharmaceutical sectors by fostering collaboration, innovation, and skill development.

Cenofex Innovations CEO Dr Sheridan Gho is an alumna of the prestigious SBE Australia Life Sciences Program (2020). SBE Australia is a premium organisation dedicated to supporting and accelerating the growth of innovative women-led businesses. With a focus on nurturing high-potential companies, SBE Australia's guidance and support play a crucial role in Cenofex's ongoing success and expansion by connecting us with excellent mentors, highly experienced entrepreneurs, and global networks.

Cenofex Innovations was honoured to partner with Hydrix through the MTP-Connect REDI program. During this program Cenofex’s CEO Dr Sheridan Gho was mentored by Peter Lewis, VP Business Development of Hydrix, providing her with the opportunity to interrogate Cenofex’s go-to-market strategy, organise valuable networking opportunities, and gain the strategic insights needed to navigate the competitive medical device landscape.

Cenofex Innovations was honoured to partner with VesTech Medical through the MTP-Connect REDI program. During this program Cenofex’s Lead Engineer Dr Chris Richards was mentored by Greg Roger, Director of Vestech, providing him with access to expert guidance, valuable networking opportunities, and the strategic insights needed to bring ground-breaking medical technologies to market.

Past Collaborations

Cenofex Innovations acknowledges the successful past collaboration with IDE Group, an industry-leading product design and development firm. Our partnership with IDE Group enabled us to leverage their extensive experience and creative problem-solving skills to develop cutting-edge medical device solutions, and verification systems for our emerging technologies.

Cenofex Innovations deeply appreciates our collaboration with the Rosenman Institute at UCSF QB3, a renowned institution dedicated to fostering innovation and entrepreneurship in the fields of biotechnology, medical technology, and digital health. Their exceptional resources and expertise were instrumental in our pursuit to revolutionise patient care and develop ground-breaking medical solutions.

Our partnership with the Rosenman Institute provided invaluable access to cutting-edge research facilities, seasoned mentors, and a vibrant community of innovators. This collaboration enabled us to refine our medical devices and navigate the complex landscape of healthcare innovation, ultimately resulting in life-enhancing solutions that have improved patient outcomes worldwide.

Boost Designs is a creative and forward-thinking product design and development firm. Working closely with Boost Designs, we harnessed their unique blend of expertise and ingenuity to create early stage prototypes and systems to tackle lymphoedema.